Overview

An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects

Status:
Completed
Trial end date:
2018-12-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the dose-response of different doses of CHF 781 pMDI on lung function and other clinical outcomes, to identify the optimal dose(s) in terms of benefit/ risk ratio for further development in the target patient population.
Phase:
Phase 2
Details
Lead Sponsor:
Chiesi Farmaceutici S.p.A.
Treatments:
Beclomethasone